LLY Stock Up 2%: Is Eli Lilly’s Retatrutide the Next Big Weight-Loss Drug?
TLDR
- Eli Lilly will file for FDA approval of retatrutide in Q1 2027, delayed from its original 2025 target
- In Phase 3 trials, patients with obesity and Type 2 diabetes lost an average of 20.8% body weight (nearly 50 lbs) at 80 weeks
- Patients with obesity and cardiovascular disease lost an average of 22.6% body weight (~55.8 lbs) at 80 weeks
- Retatrutide targets three hormones (GLP-1, GIP, glucagon), compared to one or two for rival drugs
- Analysts at TD Cowen estimate retatrutide could hit $3.8 billion in sales by 2030
Eli Lilly announced Thursday it plans to file for regulatory approval of retatrutide, its next-generation obesity drug, in the first quarter of 2027. The timeline is a delay from an earlier target of 2025. LLY stock was up 1.99% on the day.
The company said it needs more time to collect and verify manufacturing and quality-control data required by regulators.
Retatrutide is a weekly injection. It passed two additional Phase 3 clinical trials, posting weight loss results that outpace current treatments on the market.
… Continue reading the full article at the original source below.
This content is automatically aggregated. Full credit goes to the original publisher (coincentral.com).
